Respiratory syncytial virus (RSV) caused significant hospitalizations and severe outcomes in adults, especially those aged 75 ...

Nary a day goes by that the plaintiffs’ bar is not busily at work initiating a new mass tort action. Some cases expand on ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Many patients with IBD report persisting symptoms, despite resolution of the inflammatory process. Although by definition, a ...

after Pfizer acquired Array in 2019. Thomas also held leadership posts with Novartis, Bristol-Myers Squibb, Beigene, GSK and ...

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

ViiV Healthcare Announces Data Demonstrating Dovato (DTG/3TC) Is Highly Effective in Treatment-Naïve People With Advanced HIV ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

GSK is the fifth company to leave BIO in roughly a year, a group that includes Pfizer (PFE). The departures coincided with a drop in lobbying spending from the group and other challenges, STAT says.